Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.

International journal of oncology - 1 Feb 2011

Yamada Atsushi, Fujii Satoshi, Daiko Hiroyuki, Nishimura Mitsuyo, Chiba Tsutomu, Ochiai Atsushi

Abstract excerpt

EZH2 and BMI1 are transcriptional repressors and have been implicated in the progression of human cancers. Squamous cell carcinoma of the esophagus (ESCC) is one of the most aggressive carcinomas in the gastrointestinal tract and generally has an unfavorable outcome. In the present study, we immunohistochemically investigated the expression of EZH2 and BMI1 in 136 surgically resected ESCCs and adjacent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Epithelium

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Immunoenzyme Techniques

Share to Lymphatic Metastasis

Share to Polycomb Repressive Complex 1

Share to Polycomb Repressive Complex 2

Share to Survival Rate

Source

Identifiers

PMID: 21165554
DOI: 10.3892/ijo.2010.868

Genes

BMI1
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.PMID 21165554Read ↗

Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.Semantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomasSemantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation<strong> </strong>Semantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.Semantic proximity Read ↗

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.Semantic proximity Read ↗

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.Semantic proximity Read ↗

The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoterSemantic proximity Read ↗

Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancerSemantic proximity Read ↗

EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor GenesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.